2021
Risks and Benefits of Cannabis and Cannabinoids in Psychiatry
Hill KP, Gold MS, Nemeroff CB, McDonald W, Grzenda A, Widge AS, Rodriguez C, Kraguljac NV, Krystal JH, Carpenter LL. Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. American Journal Of Psychiatry 2021, 179: 98-109. PMID: 34875873, DOI: 10.1176/appi.ajp.2021.21030320.Peer-Reviewed Original ResearchConceptsPsychiatric disordersRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialTherapeutic useEvidence basePlacebo-controlled trialManagement of painBenefits of cannabisSearch of PubMedMental health cliniciansCurrent evidence basePotential side effectsSpecific medical conditionsPsychiatric indicationsFDA indicationClinical trialsHealth cliniciansMedical conditionsReference listsSide effectsChronic cannabisPsychotic disordersDrug AdministrationAdditional articlesMedicinal cannabis
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness